Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

- Males and females at least 18 years of age with moderate to severe plaque psoriasis

Exclusion Criteria:

Forms of psoriasis other than chronic plaque psoriasis
Previous exposure to IL-17A or IL-17 receptor targeting agents.
Other active or ongoing disease that may interfere with evaluation of psoriasis or places the patient at unacceptable risk
Other protocol-defined inclusion/exclusion criteria may apply